HEMA Biologics Announces FDA Approval of SEVENFACT

The following is a press release from HEMA Biologics. HEMA BiologicsTM Announces FDA Approval of SEVENFACT® [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors Louisville, KY – April 6, 2020 HEMA Biologics, LLC, (“HEMA Biologics”) today announced that the U.S. […]